{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:15:03Z","timestamp":1792178103937,"version":"4.4.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Cancer therapy advances have yet to impact global cancer mortality. One of the factors\nlimiting mortality burden reduction is the high cost of cancer drugs. Cancer drug repurposing has already\nfailed to meet expectations in terms of drug affordability. The three FDA-approved cancer\ndrugs developed under repurposing: all-trans-retinoic acid, arsenic trioxide, and thalidomide do not\ndiffer in price from other drugs developed under the classical model. Though additional factors affect\nthe whole process from inception to commercialization, the repurposing of widely used, commercially\navailable, and cheap drugs may help. This work reviews the concept of the malignant\nmetabolic phenotype and its exploitation by simultaneously blocking key metabolic processes altered\nin cancer. We elaborate on a combination called BAPST, which stands for the following\ndrugs and pathways they inhibit: Benserazide (glycolysis), Apomorphine (glutaminolysis), Pantoprazole\n(Fatty-acid synthesis), Simvastatin (mevalonate pathway), and Trimetazidine (Fatty-acid\noxidation). Their respective primary indications are:\n\u2022 Parkinson's disease (benserazide and apomorphine).\n\u2022 Peptic ulcer disease (pantoprazole).\n\u2022 Hypercholesterolemia (simvastatin).\n\u2022 Ischemic heart disease (trimetazidine).\nWhen used for their primary indication, the literature review on each of these drugs shows that\nthey have a good safety profile and lack predicted pharmacokinetic interaction among them. Based\non that, we propose that the BAPST regimen merits preclinical testing.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467214666211006123728","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T08:10:31Z","timestamp":1633680631000},"page":"815-831","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BAPST. A Combo of Common Use Drugs as Metabolic Therapy for\nCancer: A Theoretical Proposal"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-0101","authenticated-orcid":true,"given":"Adriana","family":"Romo-Perez","sequence":"first","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Dominguez-Gomez","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n\nde Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Chavez-Blanco","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n\nde Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taja-Chayeb","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n\nde Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gonzalez-Fierro","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n\nde Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Garcia-Martinez","sequence":"additional","affiliation":[{"name":"Escuela Superior de Medicina,\nInstituto Politecnico Nacional, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Correa-Basurto","sequence":"additional","affiliation":[{"name":"Laboratorio de Dise\u00f1o y Desarrollo de Nuevos F\u00e1rmacos e\nInnovaci\u00f3n Biotecnol\u00f3gica, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Duenas-Gonzalez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Mexico City, Mexico | Subdirecci\u00f3n\nde Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"Torre L.A.","year":"2016","unstructured":"Torre L.A.; Siegel R.L.; Ward E.M.; Jemal A.; Global cancer incidence and mortality rates and trends- an update. Cancer Epidemiol Biomarkers Prev 2016,25(1),16-27","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/jnci\/djx232","volume":"110","author":"Tibau A.","year":"2018","unstructured":"Tibau A.; Molto C.; Ocana A.; Templeton A.J.; Del Carpio L.P.; Del Paggio J.C.; Barnadas A.; Booth C.M.; Amir E.; Magnitude of clinical benefit of cancer drugs approved by the US food and drug administration. J Natl Cancer Inst 2018,110(5),486-492","journal-title":"J Natl Cancer Inst"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e000285","DOI":"10.1136\/esmoopen-2017-000285","volume":"3","author":"Prager G.W.","year":"2018","unstructured":"Prager G.W.; Braga S.; Bystricky B.; Qvortrup C.; Criscitiello C.; Esin E.; Sonke G.S.; Mart&#xED;nez G.A.; Frenel J.S.; Karamouzis M.; Strijbos M.; Yazici O.; Bossi P.; Banerjee S.; Troiani T.; Eniu A.; Ciardiello F.; Tabernero J.; Zielinski C.C.; Casali P.G.; Cardoso F.; Douillard J.Y.; Jezdic S.; McGregor K.; Bricalli G.; Vyas M.; Ilbawi A.; Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open 2018,3(2),e000285","journal-title":"ESMO Open"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrclinonc.2013.55","volume":"10","author":"Lopes Gde.L.","year":"2013","unstructured":"Lopes Gde.L.; de Souza J.A.; Barrios C.; Access to cancer medications in low- and middle-income countries. Nat Rev Clin Oncol 2013,10(6),314-322","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"djv370","DOI":"10.1093\/jnci\/djv370","volume":"108","author":"Zafar S.Y.","year":"2015","unstructured":"Zafar S.Y.; Financial toxicity of cancer care: It\u2019s time to intervene. J Natl Cancer Inst 2015,108(5),djv370","journal-title":"J Natl Cancer Inst"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"Paul S.M.","year":"2010","unstructured":"Paul S.M.; Mytelka D.S.; Dunwiddie C.T.; Persinger C.C.; Munos B.H.; Lindborg S.R.; Schacht A.L.; How to improve R","journal-title":"Nat Rev Drug Discov"},{"key":"ref=8","first-page":"3","volume":"1","author":"Mucke H.A.M.","year":"2015","unstructured":"Mucke H.A.M.; A new journal for the drug repurposing community. Drug repurposing, rescue. Repositioning 2015,1(1),3-4","journal-title":"Repositioning"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.clml.2015.07.634","volume":"15","author":"Tallman M.","year":"2015","unstructured":"Tallman M.; Lo-Coco F.; Barnes G.; Kruse M.; Wildner R.; Martin M.; Mueller U.; Tang B.; Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States. Clin Lymphoma Myeloma Leuk 2015,15(12),771-777","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e0134587","DOI":"10.1371\/journal.pone.0134587","volume":"10","author":"Kruse M.","year":"2015","unstructured":"Kruse M.; Wildner R.; Barnes G.; Martin M.; Mueller U.; Lo- Coco F.; Pathak A.; Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective. PLoS One 2015,10(8),e0134587","journal-title":"PLoS One"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1590\/1413-812320182410.28522017","volume":"24","author":"Paumgartten F.J.R.","year":"2019","unstructured":"Paumgartten F.J.R.; The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues. Cien Saude Colet 2019,24(10),3783-3792","journal-title":"Cien Saude Colet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: The next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.3390\/cancers12102819","volume":"12","author":"Pascale R.M.","year":"2020","unstructured":"Pascale R.M.; Calvisi D.F.; Simile M.M.; Feo C.F.; Feo F.; The Warburg effect 97 years after Its discovery. Cancers (Basel) 2020,12(10),2819","journal-title":"Cancers (Basel)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"101761","DOI":"10.1016\/j.isci.2020.101761","volume":"23","author":"Seyfried T.N.","year":"2020","unstructured":"Seyfried T.N.; Arismendi-Morillo G.; Mukherjee P.; Chinopoulos C.; On the origin of ATP synthesis in cancer. iScience 2020,23(11),101761","journal-title":"iScience"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","volume":"9","author":"de la Cruz-L&#xF3;pez K.G.","year":"2019","unstructured":"de la Cruz-L&#xF3;pez K.G.; Castro-Mu&#xF1;oz L.J.; Reyes-Hern&#xE1;ndez D.O.; Garc&#xED;a-Carranc&#xE1; A.; Manzo-Merino J.; Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol 2019,9,1143","journal-title":"Front Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/metabo10070285","volume":"10","author":"Alfarouk K.O.","year":"2020","unstructured":"Alfarouk K.O.; Ahmed S.B.M.; Elliott R.L.; Benoit A.; Alqahtani S.S.; Ibrahim M.E.; Bashir A.H.H.; Alhoufie S.T.S.; Elhassan G.O.; Wales C.C.; Schwartz L.H.; Ali H.S.; Ahmed A.; Forde P.F.; Devesa J.; Cardone R.A.; Fais S.; Harguindey S.; Reshkin S.J.; The pentose phosphate pathway dynamics in cancer and IIts dependency on intracellular pH. Metabolites 2020,10(7),285","journal-title":"Metabolites"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e2000169","DOI":"10.1002\/bies.202000169","volume":"42","author":"Kodama M.","year":"2020","unstructured":"Kodama M.; Nakayama K.I.; A second Warburg-like effect in cancer metabolism: The metabolic shift of glutamine-derived nitrogen: A shift in glutamine-derived nitrogen metabolism from glutaminolysis to de novo nucleotide biosynthesis contributes to malignant evolution of cancer. BioEssays 2020,42(12),e2000169","journal-title":"BioEssays"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00204-020-02838-8","volume":"94","author":"Mat&#xE9;s J.M.","year":"2020","unstructured":"Mat&#xE9;s J.M.; Campos-Sandoval J.A.; de Los Santos-Jim&#xE9;nez J.; M&#xE1;rquez J.; Glutaminases regulate glutathione and oxidative stress in cancer. Arch Toxicol 2020,94(8),2603-2623","journal-title":"Arch Toxicol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s12276-020-00504-8","volume":"52","author":"Yoo H.C.","year":"2020","unstructured":"Yoo H.C.; Yu Y.C.; Sung Y.; Han J.M.; Glutamine reliance in cell metabolism. Exp Mol Med 2020,52(9),1496-1516","journal-title":"Exp Mol Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40170-020-00237-2","volume":"9","author":"Nagarajan S.R.","year":"2021","unstructured":"Nagarajan S.R.; Butler L.M.; Hoy A.J.; The diversity and breadth of cancer cell fatty acid metabolism. Cancer Metab 2021,9(1),2","journal-title":"Cancer Metab"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/1541-7786.MCR-18-0347","volume":"17","author":"Balaban S.","year":"2019","unstructured":"Balaban S.; Nassar Z.D.; Zhang A.Y.; Hosseini-Beheshti E.; Centenera M.M.; Schreuder M.; Lin H.M.; Aishah A.; Varney B.; Liu-Fu F.; Lee L.S.; Nagarajan S.R.; Shearer R.F.; Hardie R.A.; Raftopulos N.L.; Kakani M.S.; Saunders D.N.; Holst J.; Horvath L.G.; Butler L.M.; Hoy A.J.; Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Mol Cancer Res 2019,17(4),949-962","journal-title":"Mol Cancer Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"188351","DOI":"10.1016\/j.bbcan.2020.188351","volume":"1873","author":"G&#xF6;bel A.","year":"2020","unstructured":"G&#xF6;bel A.; Rauner M.; Hofbauer L.C.; Rachner T.D.; Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer 2020,1873(2),188351","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.3390\/cells9122600","volume":"9","author":"De Oliveira M.P.","year":"2020","unstructured":"De Oliveira M.P.; Liesa M.; The role of mitochondrial fat oxidation in cancer cell proliferation and survival. Cells 2020,9(12),2600","journal-title":"Cells"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1113\/expphysiol.1985.sp002935","volume":"70","author":"Newsholme E.A.","year":"1985","unstructured":"Newsholme E.A.; Crabtree B.; Ardawi M.S.M.; Glutamine metabolism in lymphocytes: Its biochemical, physiological and clinical importance. Q J Exp Physiol 1985,70(4),473-489","journal-title":"Q J Exp Physiol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jnci\/62.3.CO3","volume":"62","author":"Hume D.A.","year":"1979","unstructured":"Hume D.A.; Weidemann M.J.; Role and regulation of glucose metabolism in proliferating cells. J Natl Cancer Inst 1979,62(1),3-8","journal-title":"J Natl Cancer Inst"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jnc.13630","volume":"138","author":"Dienel G.A.","year":"2016","unstructured":"Dienel G.A.; Cruz N.F.; Aerobic glycolysis during brain activation: Adrenergic regulation and influence of norepinephrine on astrocytic metabolism. J Neurochem 2016,138(1),14-52","journal-title":"J Neurochem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1073\/pnas.88.13.5829","volume":"88","author":"Prichard J.","year":"1991","unstructured":"Prichard J.; Rothman D.; Novotny E.; Petroff O.; Kuwabara T.; Avison M.; Howseman A.; Hanstock C.; Shulman R.; Lactate rise detected by 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA 1991,88(13),5829-5831","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/261702a0","volume":"261","author":"Wang T.","year":"1976","unstructured":"Wang T.; Marquardt C.; Foker J.; Aerobic glycolysis during lymphocyte proliferation. Nature 1976,261(5562),702-705","journal-title":"Nature"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"E700","DOI":"10.1152\/ajpendo.00052.2013","volume":"305","author":"Mohammad M.A.","year":"2013","unstructured":"Mohammad M.A.; Haymond M.W.; Regulation of lipid synthesis genes and milk fat production in human mammary epithelial cells during secretory activation. Am J Physiol Endocrinol Metab 2013,305(6),E700-E716","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ydbio.2017.12.001","volume":"447","author":"Teuwen L.A.","year":"2019","unstructured":"Teuwen L.A.; Geldhof V.; Carmeliet P.; How glucose, glutamine and fatty acid metabolism shape blood and lymph vessel development. Dev Biol 2019,447(1),90-102","journal-title":"Dev Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/0020-711X(88)90303-5","volume":"25","author":"Griffiths M.","year":"1993","unstructured":"Griffiths M.; Keast D.; Patrick G.; Crawford M.; Palmer T.N.; The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro. Int J Biochem 1993,25(12),1749-1755","journal-title":"Int J Biochem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.lungcan.2018.10.016","volume":"126","author":"Meijer T.W.H.","year":"2018","unstructured":"Meijer T.W.H.; Peeters W.J.M.; Dubois L.J.; van Gisbergen M.W.; Biemans R.; Venhuizen J-H.; Span P.N.; Bussink J.; Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. Lung Cancer 2018,126,32-40","journal-title":"Lung Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"63551","DOI":"10.18632\/oncotarget.18854","volume":"8","author":"Sun L.","year":"2017","unstructured":"Sun L.; Yin Y.; Clark L.H.; Sun W.; Sullivan S.A.; Tran A.Q.; Han J.; Zhang L.; Guo H.; Madugu E.; Pan T.; Jackson A.L.; Kilgore J.; Jones H.M.; Gilliam T.P.; Zhou C.; Bae-Jump V.L.; Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer. Oncotarget 2017,8(38),63551-63561","journal-title":"Oncotarget"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1158\/1535-7163.MCT-14-0183","volume":"13","author":"Schlaepfer I.R.","year":"2014","unstructured":"Schlaepfer I.R.; Rider L.; Rodrigues L.U.; Gij&#xF3;n M.A.; Pac C.T.; Romero L.; Cimic A.; Sirintrapun S.J.; Glod&#xE9; L.M.; Eckel R.H.; Cramer S.D.; Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther 2014,13(10),2361-2371","journal-title":"Mol Cancer Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11307-014-0814-4","volume":"17","author":"Schlaepfer I.R.","year":"2015","unstructured":"Schlaepfer I.R.; Glod&#xE9; L.M.; Hitz C.A.; Pac C.T.; Boyle K.E.; Maroni P.; Deep G.; Agarwal R.; Lucia S.M.; Cramer S.D.; Serkova N.J.; Eckel R.H.; Inhibition of lipid oxidation increases glucose metabolism and enhances 2-deoxy-2-[18F]Fluoro-d-glucose uptake in prostate cancer mouse xenografts. Mol Imaging Biol 2015,17(4),529-538","journal-title":"Mol Imaging Biol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.cellsig.2014.07.024","volume":"26","author":"Wu H.","year":"2014","unstructured":"Wu H.; Li Z.; Yang P.; Zhang L.; Fan Y.; Li Z.; PKM2 depletion induces the compensation of glutaminolysis through &#x3B2;-catenin\/c-Myc pathway in tumor cells. Cell Signal 2014,26(11),2397-2405","journal-title":"Cell Signal"},{"key":"ref=37","first-page":"1","author":"Cardoso H.J.","year":"2021","unstructured":"Cardoso H.J.; Figueira M.I.; Vaz C.V.; Carvalho T.M.A.; Br&#xE1;s L.A.; Madureira P.A.; Oliveira P.J.; Sard&#xE3;o V.A.; Socorro S.; Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5&#x3B1;-dihydrotestosterone regulation. Cell Oncol 2021,1-19","journal-title":"Cell Oncol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11307-012-0587-6","volume":"15","author":"Sankaranarayanapillai M.","year":"2013","unstructured":"Sankaranarayanapillai M.; Zhang N.; Baggerly K.A.; Gelovani J.G.; Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy. Mol Imaging Biol 2013,15(2),136-147","journal-title":"Mol Imaging Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3892\/or.2015.4077","volume":"34","author":"Cervantes-Madrid D.","year":"2015","unstructured":"Cervantes-Madrid D.; Due&#xF1;as-Gonz&#xE1;lez A.; Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. Oncol Rep 2015,34(3),1533-1542","journal-title":"Oncol Rep"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3892\/ol.2017.5615","volume":"13","author":"Cervantes-Madrid D.","year":"2017","unstructured":"Cervantes-Madrid D.; Dominguez-Gomez G.; Gonzalez-Fierro A.; Perez-Cardenas E.; Taja-Chayeb L.; Trejo-Becerril C.; Duenas-Gonzalez A.; Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer. Oncol Lett 2017,13(3),1905-1910","journal-title":"Oncol Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","volume":"64","author":"Kridel S.J.","year":"2004","unstructured":"Kridel S.J.; Axelrod F.; Rozenkrantz N.; Smith J.W.; Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004,64(6),2070-2075","journal-title":"Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"690492","DOI":"10.1155\/2015\/690492","volume":"2015","author":"Cervantes-Madrid D.","year":"2015","unstructured":"Cervantes-Madrid D.; Romero Y.; Due&#xF1;as-Gonz&#xE1;lez A.; Reviving lonidamine and 6-diazo-5-Oxo-L-norleucine to be used in combination for metabolic cancer therapy. BioMed Res Int 2015,2015,690492","journal-title":"BioMed Res Int"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.3892\/ol.2020.11838","volume":"20","author":"Schcolnik-Cabrera A.","year":"2020","unstructured":"Schcolnik-Cabrera A.; Chavez-Blanco A.; Dominguez-Gomez G.; Juarez M.; Lai D.; Hua S.; Tovar A.R.; Diaz-Chavez J.; Duenas-Gonzalez A.; The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. Oncol Lett 2020,20(3),3053-3060","journal-title":"Oncol Lett"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1038\/s41598-021-84538-6","volume":"11","author":"Schcolnik-Cabrera A.","year":"2021","unstructured":"Schcolnik-Cabrera A.; Chavez-Blanco A.; Dominguez-Gomez G.; Juarez M.; Vargas-Castillo A.; Ponce-Toledo R.I.; Lai D.; Hua S.; Tovar A.R.; Torres N.; Perez-Montiel D.; Diaz-Chavez J.; Duenas-Gonzalez A.; Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Sci Rep 2021,11(1),5222","journal-title":"Sci Rep"},{"key":"ref=45","first-page":"79","author":"H&#xE4;ggstr&#xF6;m L.","year":"1991","unstructured":"H&#xE4;ggstr&#xF6;m L.;  Energetics of glutaminolysis \u2013 a theoretical evaluation 1991,79-81","journal-title":"Energetics of glutaminolysis \u2013 a theoretical evaluation"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003495-197611050-00001","volume":"11","author":"Pinder R.M.","year":"1976","unstructured":"Pinder R.M.; Brogden R.N.; Sawyer P.R.; Speight T.M.; Avery G.S.; Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976,11(5),329-377","journal-title":"Drugs"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF00614388","volume":"7","author":"Schwartz D.E.","year":"1974","unstructured":"Schwartz D.E.; Jordan J.C.; Ziegler W.H.; Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat. Eur J Clin Pharmacol 1974,7(1),39-45","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phrs.2016.08.016","volume":"113","author":"Druzhyna N.","year":"2016","unstructured":"Druzhyna N.; Szczesny B.; Olah G.; M&#xF3;dis K.; Asimakopoulou A.; Pavlidou A.; Szoleczky P.; Ger&#xF6; D.; Yanagi K.; T&#xF6;r&#xF6; G.; L&#xF3;pez-Garc&#xED;a I.; Myrianthopoulos V.; Mikros E.; Zatarain J.R.; Chao C.; Papapetropoulos A.; Hellmich M.R.; Szabo C.; Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine &#x3B2;-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. Pharmacol Res 2016,113(Pt A),18-37","journal-title":"Pharmacol Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e1900035","DOI":"10.1002\/minf.201900035","volume":"39","author":"Sebastian J.","year":"2020","unstructured":"Sebastian J.; Rathinasamy K.; Benserazide perturbs Kif15\u2010kinesin binding protein interaction with prolonged metaphase and defects in chromosomal congression: A study based on in silico modeling and cell culture. Mol Inform 2020,39(3),e1900035","journal-title":"Mol Inform"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1900035","DOI":"10.1002\/minf.201900035","volume":"39","author":"Untereiner A.A.","year":"2020","unstructured":"Untereiner A.A.; Pavlidou A.; Druzhyna N.; Papapetropoulos A.; Hellmich M.R.; Szabo C.; Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells. Biochem. Pharmacol. 2018, 149, 174\u2013185. based on in silico modeling and cell culture. Mol Inform 2020,39(3),1900035","journal-title":"Mol Inform"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1158\/0008-5472.CAN-14-1716","volume":"74","author":"Alli E.","year":"2014","unstructured":"Alli E.; Solow-Cordero D.; Casey S.C.; Ford J.M.; Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res 2014,74(21),6205-6215","journal-title":"Cancer Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40064-015-1063-y","volume":"4","author":"Kelts J.L.","year":"2015","unstructured":"Kelts J.L.; Cali J.J.; Duellman S.J.; Shultz J.; Altered cytotoxicity of ROS-inducing compounds by sodium pyruvate in cell culture medium depends on the location of ROS generation. Springerplus 2015,4(1),269","journal-title":"Springerplus"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ijc.32756","volume":"147","author":"Zhou Y.","year":"2020","unstructured":"Zhou Y.; Huang Z.; Su J.; Li J.; Zhao S.; Wu L.; Zhang J.; He Y.; Zhang G.; Tao J.; Zhou J.; Chen X.; Peng C.; Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer 2020,147(1),139-151","journal-title":"Int J Cancer"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-017-0530-4","volume":"36","author":"Li W.","year":"2017","unstructured":"Li W.; Zheng M.; Wu S.; Gao S.; Yang M.; Li Z.; Min Q.; Sun W.; Chen L.; Xiang G.; Li H.; Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res 2017,36(1),58","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbrc.2012.05.063","volume":"423","author":"Kwon O.H.","year":"2012","unstructured":"Kwon O.H.; Kang T.W.; Kim J.H.; Kim M.; Noh S.M.; Song K.S.; Yoo H.S.; Kim W.H.; Xie Z.; Pocalyko D.; Kim S.Y.; Kim Y.S.; Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 2012,423(1),38-44","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.3748\/wjg.v18.i30.4037","volume":"18","author":"Lim J.Y.","year":"2012","unstructured":"Lim J.Y.; Yoon S.O.; Seol S.Y.; Hong S.W.; Kim J.W.; Choi S.H.; Cho J.Y.; Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 2012,18(30),4037-4043","journal-title":"World J Gastroenterol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13277-010-0109-6","volume":"32","author":"Qiu M.Z.","year":"2011","unstructured":"Qiu M.Z.; Han B.; Luo H.Y.; Zhou Z.W.; Wang Z.Q.; Wang F.H.; Li Y.H.; Xu R.H.; Expressions of hypoxia-inducible factor-1&#x3B1; and hexokinase-II in gastric adenocarcinoma: The impact on prognosis and correlation to clinicopathologic features. Tumour Biol 2011,32(1),159-166","journal-title":"Tumour Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40268-018-0230-3","volume":"18","author":"Auffret M.","year":"2018","unstructured":"Auffret M.; Drapier S.; V&#xE9;rin M.; The Many Faces of Apomorphine: Lessons from the past and challenges for the future. Drugs R D 2018,18(2),91-107","journal-title":"Drugs R D"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2018.10.052","volume":"843","author":"Auffret M.","year":"2019","unstructured":"Auffret M.; Drapier S.; V&#xE9;rin M.; New tricks for an old dog: A repurposing approach of apomorphine. Eur J Pharmacol 2019,843,66-79","journal-title":"Eur J Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0278-5846(88)90033-4","volume":"12","author":"Lal S.","year":"1988","unstructured":"Lal S.; Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1988,12(2-3),117-164","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/adt.2015.680","volume":"13","author":"Morales-Rosado J.A.","year":"2015","unstructured":"Morales-Rosado J.A.; Cousin M.A.; Ebbert J.O.; Klee E.W.; A Critical Review of repurposing apomorphine for smoking cessation. Assay Drug Dev Technol 2015,13(10),612-622","journal-title":"Assay Drug Dev Technol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000051001","volume":"67","author":"Altwein J.E.","year":"2001","unstructured":"Altwein J.E.; Keuler F.U.; Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 2001,67(4),257-263","journal-title":"Urol Int"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"13883","DOI":"10.1038\/s41598-018-32306-4","volume":"8","author":"Ban&#xFA;s-Mulet A.","year":"2018","unstructured":"Ban&#xFA;s-Mulet A.; Etxabe A.; Cornet-Masana J.M.; Torrente M.&#xC1;.; Lara-Castillo M.C.; Palomo L.; Nomdedeu M.; D&#xED;az-Bey&#xE1; M.; Sol&#xE9; F.; Nomdedeu B.; Esteve J.; Risue&#xF1;o R.M.; Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. Sci Rep 2018,8(1),13883","journal-title":"Sci Rep"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0014-2999(01)01491-1","volume":"433","year":"2001","unstructured":"Chiarenza, A .; Scarselli, M .; Novi, F .; Lempereur, L .; Bernardini, R .; Corsini, G. U .; Maggio. Apomorphine, dopamine and phenylethylamine reduces the proportion of phosphorylated insulin receptor substrate 1. Eur J Pharmacol 2001,433(1),47-54","journal-title":"Eur J Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF03033258","volume":"1","author":"Maggio R.","year":"2000","unstructured":"Maggio R.; Armogida M.; Scarselli M.; Salvadori F.; Longoni B.; Pardini C.; Chiarenza A.; Chiacchio S.; Vaglini F.; Bernardini R.; Colzi A.; Corsini G.U.; Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells. Neurotox Res 2000,1(4),285-297","journal-title":"Neurotox Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1248\/bpb1978.13.426","volume":"13","author":"Kondo Y.","year":"1990","unstructured":"Kondo Y.; Imai Y.; Hojo H.; Endo T.; Nozoe S.; Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine. J Pharmacobiodyn 1990,13(7),426-431","journal-title":"J Pharmacobiodyn"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1073\/pnas.71.6.2525","volume":"71","author":"Prasad K.N.","year":"1974","unstructured":"Prasad K.N.; Gilmer K.N.; Demonstration of dopamine-sensitive adenylate cyclase in malignant neuroblastoma cells and change in sensitivity of adenylate cyclase to catecholamines in &#x201C;differentiated&#x201D; cells. Proc Natl Acad Sci USA 1974,71(6),2525-2529","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-7091-6369-6_5","volume":"55","author":"Scarselli M.","year":"1999","unstructured":"Scarselli M.; Barbier P.; Salvadori F.; Armogida M.; Collecchi P.; Pardini C.; Vaglini F.; Maggio R.; Corsini G.U.; Apomorphine has a potent antiproliferative effect on Chinese hamster ovary cells. J Neural Transm Suppl 1999,55,47-55","journal-title":"J Neural Transm Suppl"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.freeradbiomed.2020.05.001","volume":"154","author":"Lee J-Y.","year":"2020","unstructured":"Lee J-Y.; Ham J.; Lim W.; Song G.; Apomorphine facilitates loss of respiratory chain activity in human epithelial ovarian cancer and inhibits angiogenesis in vivo. Free Radic Biol Med 2020,154,95-104","journal-title":"Free Radic Biol Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/REP-20-0230","volume":"160","author":"Lee J.Y.","year":"2020","unstructured":"Lee J.Y.; Ham J.; Lim W.; Song G.; Apomorphine induces mitochondrial-dysfunction-dependent apoptosis in choriocarcinoma. Reproduction 2020,160(3),367-377","journal-title":"Reproduction"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1158\/0008-5472.CAN-18-1022","volume":"78","author":"Singh M.","year":"2018","unstructured":"Singh M.; Venugopal C.; Tokar T.; McFarlane N.; Subapanditha M.K.; Qazi M.; Bakhshinyan D.; Vora P.; Murty N.K.; Jurisica I.; Singh S.K.; Therapeutic targeting of the premetastatic stage in human lung-to-brain metastasis. Cancer Res 2018,78(17),5124-5134","journal-title":"Cancer Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"13485","DOI":"10.1073\/pnas.0605993103","volume":"103","author":"Meredith E.J.","year":"2006","unstructured":"Meredith E.J.; Holder M.J.; Ros&#xE9;n A.; Lee A.D.; Dyer M.J.S.; Barnes N.M.; Gordon J.; Dopamine targets cycling B cells independent of receptors\/transporter for oxidative attack: Implications for non-Hodgkin\u2019s lymphoma. Proc Natl Acad Sci USA 2006,103(36),13485-13490","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/leu.2017.52","volume":"31","author":"Etxabe A.","year":"2017","unstructured":"Etxabe A.; Lara-Castillo M.C.; Cornet-Masana J.M.; Ban&#xFA;s- Mulet A.; Nomdedeu M.; Torrente M.A.; Pratcorona M.; D&#xED;az-Bey&#xE1; M.; Esteve J.; Risue&#xF1;o R.M.; Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: A promising novel therapeutic target. Leukemia 2017,31(11),2288-2302","journal-title":"Leukemia"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10637-019-00784-6","volume":"38","author":"Rodrigues-Junior D.M.","year":"2020","unstructured":"Rodrigues-Junior D.M.; de Almeida Pontes N.M.; de Albuquerque G.E.; Carlin V.; Perecim G.P.; Raminelli C.; Vettore A.L.; Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells. Invest New Drugs 2020,38(1),70-78","journal-title":"Invest New Drugs"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.bbrc.2017.04.151","volume":"487","author":"Jung Y.S.","year":"2017","unstructured":"Jung Y.S.; Lee S.O.; Apomorphine suppresses TNF-&#x3B1;-induced MMP-9 expression and cell invasion through inhibition of ERK\/AP-1 signaling pathway in MCF-7 cells. Biochem Biophys Res Commun 2017,487(4),903-909","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1471-4159.1984.tb00917.x","volume":"43","author":"Berry-Kravis E.","year":"1984","unstructured":"Berry-Kravis E.; Freedman S.B.; Dawson G.; Specific receptor- mediated inhibition of cyclic AMP synthesis by dopamine in a neuroblastoma X brain hybrid cell line NCB-20. J Neurochem 1984,43(2),413-420","journal-title":"J Neurochem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbrc.2013.06.110","volume":"438","author":"Thomas A.G.","year":"2013","unstructured":"Thomas A.G.; Rojas C.; Tanega C.; Shen M.; Simeonov A.; Boxer M.B.; Auld D.S.; Ferraris D.V.; Tsukamoto T.; Slusher B.S.; Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. Biochem Biophys Res Commun 2013,438(2),243-248","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1111\/cas.13421","volume":"108","author":"Kitayama K.","year":"2017","unstructured":"Kitayama K.; Yashiro M.; Morisaki T.; Miki Y.; Okuno T.; Kinoshita H.; Fukuoka T.; Kasashima H.; Masuda G.; Hasegawa T.; Sakurai K.; Kubo N.; Hirakawa K.; Ohira M.; Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer. Cancer Sci 2017,108(12),2462-2469","journal-title":"Cancer Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","volume":"19","author":"Yang L.","year":"2017","unstructured":"Yang L.; Venneti S.; Nagrath D.; Glutaminolysis: A hallmark of cancer metabolism. Annu Rev Biomed Eng 2017,19(1),163-194","journal-title":"Annu Rev Biomed Eng"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"39640","DOI":"10.18632\/oncotarget.17387","volume":"8","author":"Guo D.","year":"2017","unstructured":"Guo D.; Wang C.; Wang Q.; Qiao Z.; Tang H.; Pantoprazole blocks the JAK2\/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget 2017,8(24),39640-39648","journal-title":"Oncotarget"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"109478","DOI":"10.1016\/j.biopha.2019.109478","volume":"120","author":"Lu Z.N.","year":"2019","unstructured":"Lu Z.N.; Shi Z.Y.; Dang Y.F.; Cheng Y.N.; Guan Y.H.; Hao Z.J.; Tian B.; He H.W.; Guo X.L.; Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother 2019,120,109478","journal-title":"Biomed Pharmacother"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.7197\/223.vi.499367","volume":"40","author":"Erg&#xFC;l M.","year":"2018","unstructured":"Erg&#xFC;l M.; Erg&#xFC;l M.; Protein pump inhibitors esomeprazole and pantoprazole increase the chemosensitivity of Cml Cells against Imatinib. Cumhur Med J 2018,40(4),351-355","journal-title":"Cumhur Med J"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.cellbi.2009.05.004","volume":"33","author":"Chen M.","year":"2009","unstructured":"Chen M.; Zou X.; Luo H.; Cao J.; Zhang X.; Zhang B.; Liu W.; Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int 2009,33(9),1008-1019","journal-title":"Cell Biol Int"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.intimp.2013.07.021","volume":"17","author":"Huang S.","year":"2013","unstructured":"Huang S.; Chen M.; Ding X.; Zhang X.; Zou X.; Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway. Int Immunopharmacol 2013,17(3),585-592","journal-title":"Int Immunopharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1634\/theoncologist.2018-0621","volume":"24","author":"Hansen A.R.","year":"2019","unstructured":"Hansen A.R.; Tannock I.F.; Templeton A.; Chen E.; Evans A.; Knox J.; Prawira A.; Sridhar S.S.; Tan S.; Vera-Badillo F.; Wang L.; Wouters B.G.; Joshua A.M.; Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): Phase II trial of high dose pantoprazole (Autophagy Inhibitor) with docetaxel in metastatic castration-resistant prostate cancer (MCRPC). Oncologist 2019,24(9),1188-1194","journal-title":"Oncologist"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.3892\/ol.2018.8199","volume":"15","author":"Kuang Y.","year":"2018","unstructured":"Kuang Y.; Wang S.; Tang L.; Hai J.; Yan G.; Liao L.; Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H-ATPase expression and activity. Oncol Lett 2018,15(5),7279-7290","journal-title":"Oncol Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/bjc.2015.17","volume":"112","author":"Tan Q.","year":"2015","unstructured":"Tan Q.; Joshua A.M.; Saggar J.K.; Yu M.; Wang M.; Kanga N.; Zhang J.Y.; Chen X.; Wouters B.G.; Tannock I.F.; Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J Cancer 2015,112(5),832-840","journal-title":"Br J Cancer"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"6766","DOI":"10.1158\/1078-0432.CCR-13-0128","volume":"19","author":"Patel K.J.","year":"2013","unstructured":"Patel K.J.; Lee C.; Tan Q.; Tannock I.F.; Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: A potential strategy to improve the therapy of solid tumors. Clin Cancer Res 2013,19(24),6766-6776","journal-title":"Clin Cancer Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.canlet.2014.10.016","volume":"356","author":"Zhang B.","year":"2015","unstructured":"Zhang B.; Yang Y.; Shi X.; Liao W.; Chen M.; Cheng A.S.L.; Yan H.; Fang C.; Zhang S.; Xu G.; Shen S.; Huang S.; Chen G.; Lv Y.; Ling T.; Zhang X.; Wang L.; Zhuge Y.; Zou X.; Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt\/GSK-&#x3B2;\/&#x3B2;- catenin signaling and epithelial-mesenchymal transition. Cancer Lett 2015,356(2 Pt B),704-712","journal-title":"Cancer Lett"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/jcb.24122","volume":"113","author":"Chen M.","year":"2012","unstructured":"Chen M.; Huang S-L.; Zhang X-Q.; Zhang B.; Zhu H.; Yang V.W.; Zou X-P.; Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases\/mTOR\/HIF-1&#x3B1;\/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 2012,113(7),2474-2487","journal-title":"J Cell Biochem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"58801","DOI":"10.18632\/oncotarget.18522","volume":"8","author":"Wang X.","year":"2017","unstructured":"Wang X.; Liu C.; Wang J.; Fan Y.; Wang Z.; Wang Y.; Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget 2017,8(35),58801-58808","journal-title":"Oncotarget"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2478\/acph-2020-0020","volume":"70","author":"Ihraiz W.G.","year":"2020","unstructured":"Ihraiz W.G.; Ahram M.; Bardaweel S.K.; Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells. Acta Pharm 2020,70(2),179-190","journal-title":"Acta Pharm"},{"key":"ref=93","first-page":"752","volume":"7","author":"Sarankumar M.S.","year":"2018","unstructured":"Sarankumar M.S.; Suresh A.; Lactate transport and acidosis as target for tumor regression by drug repositioning in lung carcinogenesis model. World J Pharm Pharm Sci 2018,7(8),752-773","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41419-019-2020-4","volume":"10","author":"Xiao J.","year":"2019","unstructured":"Xiao J.; Wang F.; Lu H.; Xu S.; Zou L.; Tian Q.; Fu Y.; Lin X.; Liu L.; Yuan P.; Ni X.; Ma T.; Zeng F.; Xue P.; Xiu R.; Zhang J.; Ji X.; Hu H.; Lu S.; Dai H.; Li Y.; Chu Q.; Zhao X.; Duan Q.; Zhu F.; Targeting the COX2\/MET\/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell Death Dis 2019,10(10),777","journal-title":"Cell Death Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10571-018-0623-4","volume":"38","author":"Geeviman K.","year":"2018","unstructured":"Geeviman K.; Babu D.; Prakash Babu P.; Pantoprazole induces mitochondrial apoptosis and attenuates NF-KB signaling in glioma cells. Cell Mol Neurobiol 2018,38(8),1491-1504","journal-title":"Cell Mol Neurobiol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"22460","DOI":"10.18632\/oncotarget.7984","volume":"7","author":"Zeng X.","year":"2016","unstructured":"Zeng X.; Liu L.; Zheng M.; Sun H.; Xiao J.; Lu T.; Huang G.; Chen P.; Zhang J.; Zhu F.; Li H.; Duan Q.; Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget 2016,7(16),22460-22473","journal-title":"Oncotarget"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3892\/ol.2015.3912","volume":"11","author":"Shen Y.","year":"2016","unstructured":"Shen Y.; Chen M.; Huang S.; Zou X.; Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2. Oncol Lett 2016,11(1),717-722","journal-title":"Oncol Lett"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3892\/or.2013.2524","volume":"30","author":"Shen W.","year":"2013","unstructured":"Shen W.; Zou X.; Chen M.; Shen Y.; Huang S.; Guo H.; Zhang L.; Liu P.; Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho-LRP6 expression in Wnt\/&#x3B2;-catenin signaling. Oncol Rep 2013,30(2),851-855","journal-title":"Oncol Rep"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2019.03.029","volume":"452","author":"Zhang B.","year":"2019","unstructured":"Zhang B.; Ling T.; Zhaxi P.; Cao Y.; Qian L.; Zhao D.; Kang W.; Zhang W.; Wang L.; Xu G.; Zou X.; Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression. Cancer Lett 2019,452,23-30","journal-title":"Cancer Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.2147\/OTT.S161198","volume":"11","author":"Chen M.","year":"2018","unstructured":"Chen M.; Lu J.; Wei W.; Lv Y.; Zhang X.; Yao Y.; Wang L.; Ling T.; Zou X.; Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases\/PI3K\/Akt\/mTOR\/HIF-1&#x3B1; signaling pathway through TSC1\/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. OncoTargets Ther 2018,11,6705-6722","journal-title":"OncoTargets Ther"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4149\/neo_2012_019","volume":"59","author":"Shen Y.","year":"2012","unstructured":"Shen Y.; Wu Y.; Chen M.; Shen W.; Huang S.; Zhang L.; Zou X.; Effects of pantoprazole as a HIF-1&#x3B1; inhibitor on human gastric adenocarcinoma sgc-7901 cells. Neoplasma 2012,59(2),142-149","journal-title":"Neoplasma"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1158\/1078-0432.CCR-04-1065","volume":"10","author":"Yeo M.","year":"2004","unstructured":"Yeo M.; Kim D.K.; Kim Y.B.; Oh T.Y.; Lee J.E.; Cho S.W.; Kim H.C.; Hahm K.B.; Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 2004,10(24),8687-8696","journal-title":"Clin Cancer Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"8:50","DOI":"10.1186\/s13578-018-0248-9","year":"2018","unstructured":"Koh, J.S .; Joo, M.K .; Park, J.J .; Yoo, H.S .; Choi, B. Il .; Lee, B.J .; Chun, H.J .; Lee, S.W. Inhibition of STAT3 in gastric cancer: Role of pantoprazole as SHP-1 inducer. Cell Biosci 2018,8:50","journal-title":"Cell Biosci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41419-018-0642-6","volume":"9","author":"Cao Y.","year":"2018","unstructured":"Cao Y.; Chen M.; Tang D.; Yan H.; Ding X.; Zhou F.; Zhang M.; Xu G.; Zhang W.; Zhang S.; Zhuge Y.; Wang L.; Zou X.; The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses. Cell Death Dis 2018,9(6),604","journal-title":"Cell Death Dis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/cancers12030640","volume":"12","author":"Tozzi M.","year":"2020","unstructured":"Tozzi M.; S&#xF8;rensen C.E.; Magni L.; Christensen N.M.; Bouazzi R.; Buch C.M.; Stefanini M.; Duranti C.; Arcangeli A.; Novak I.; Proton pump inhibitors reduce pancreatic adenocarcinoma progression by selectively targeting H+, K+-ATPases in pancreatic cancer and stellate cells. Cancers (Basel) 2020,12(3),640","journal-title":"Cancers (Basel)"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biopha.2010.06.012","volume":"65","author":"Vishvakarma N.K.","year":"2011","unstructured":"Vishvakarma N.K.; Singh S.M.; Mechanisms of tumor growth retardation by modulation of pH regulation in the tumor-microenvironment of a murine T cell lymphoma. Biomed Pharmacother 2011,65(1),27-39","journal-title":"Biomed Pharmacother"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.neo.2016.04.003","volume":"18","author":"Tan Q.","year":"2016","unstructured":"Tan Q.; Wang M.; Yu M.; Zhang J.; Bristow R.G.; Hill R.P.; Tannock I.F.; Role of autophagy as a survival mechanism for hypoxic cells in tumors. Neoplasia 2016,18(6),347-355","journal-title":"Neoplasia"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00280-017-3298-5","volume":"79","author":"Tan Q.","year":"2017","unstructured":"Tan Q.; Joshua A.M.; Wang M.; Bristow R.G.; Wouters B.G.; Allen C.J.; Tannock I.F.; Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. Cancer Chemother Pharmacol 2017,79(5),959-969","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1021\/jm501543u","volume":"58","author":"Fako V.E.","year":"2015","unstructured":"Fako V.E.; Wu X.; Pflug B.; Liu J.Y.; Zhang J.T.; Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J Med Chem 2015,58(2),778-784","journal-title":"J Med Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"104","DOI":"10.15420\/ecr.2018.15.2","volume":"13","author":"Guarini G.","year":"2018","unstructured":"Guarini G.; Huqi A.; Morrone D.; Capozza P.F.G.; Marzilli M.; Trimetazidine and other metabolic modifiers. Eur Cardiol 2018,13(2),104-111","journal-title":"Eur Cardiol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1472-8206.2003.00154.x","volume":"17","author":"Stanley W.C.","year":"2003","unstructured":"Stanley W.C.; Marzilli M.; Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine. Fundam Clin Pharmacol 2003,17(2),133-145","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=112","first-page":"13950","volume":"9","author":"Liu Z.","year":"2016","unstructured":"Liu Z.; Wang D.; Liu D.; Liu J.; Zhou G.; Trimetazidine protects against LPS-induced acute lung injury through MTOR\/SGK1 Pathway. Int J Clin Exp Med 2016,9(7),13950-13957","journal-title":"Int J Clin Exp Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1023\/A:1002801504611","volume":"130","author":"Tikhaze A.K.","year":"2000","unstructured":"Tikhaze A.K.; Lankin V.Z.; Zharova E.A.; Kolycheva S.V.; Trimetazidine as indirect antioxidant. Bull Exp Biol Med 2000,130(10),951-953","journal-title":"Bull Exp Biol Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0300-483X(03)00259-2","volume":"191","author":"Singh D.","year":"2003","unstructured":"Singh D.; Chander V.; Chopra K.; Carvedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats. Toxicology 2003,191(2-3),143-151","journal-title":"Toxicology"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2459\/JCM.0b013e328332e873","volume":"11","author":"Lestuzzi C.","year":"2010","unstructured":"Lestuzzi C.; Crivellari D.; Rigo F.; Viel E.; Meneguzzo N.; Capecitabine cardiac toxicity presenting as effort angina: A case report. J Cardiovasc Med (Hagerstown) 2010,11(9),700-703","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/000331970305400212","volume":"54","author":"Tallarico D.","year":"2003","unstructured":"Tallarico D.; Rizzo V.; Di Maio F.; Petretto F.; Bianco G.; Placanica G.; Marziali M.; Paravati V.; Gueli N.; Meloni F.; Campbell S.V.; Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 2003,54(2),219-227","journal-title":"Angiology"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/jrr\/rraa043","volume":"61","author":"Zhang J.","year":"2020","unstructured":"Zhang J.; He X.; Bai X.; Sun Y.; Jiang P.; Wang X.; Li W.; Zhang Y.; Protective effect of trimetazidine in radiation-induced cardiac fibrosis in mice. J Radiat Res (Tokyo) 2020,61(5),657-665","journal-title":"J Radiat Res (Tokyo)"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jcsm.12097","volume":"7","author":"Ferraro E.","year":"2016","unstructured":"Ferraro E.; Pin F.; Gorini S.; Pontecorvo L.; Ferri A.; Mollace V.; Costelli P.; Rosano G.; Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. J Cachexia Sarcopenia Muscle 2016,7(4),449-457","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"113938","DOI":"10.18632\/oncotarget.23044","volume":"8","author":"Gatta L.","year":"2017","unstructured":"Gatta L.; Vitiello L.; Gorini S.; Chiandotto S.; Costelli P.; Giammarioli A.M.; Malorni W.; Rosano G.; Ferraro E.; Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumor-bearing c26 mice. Oncotarget 2017,8(69),113938-113956","journal-title":"Oncotarget"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jcsm.12226","volume":"8","author":"Molinari F.","year":"2017","unstructured":"Molinari F.; Pin F.; Gorini S.; Chiandotto S.; Pontecorvo L.; Penna F.; Rizzuto E.; Pisu S.; Musar&#xF2; A.; Costelli P.; Rosano G.; Ferraro E.; The mitochondrial metabolic reprogramming agent trimetazidine as an \u2018exercise mimetic\u2019 in cachectic C26-bearing mice. J Cachexia Sarcopenia Muscle 2017,8(6),954-973","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3892\/mmr.2020.11309","volume":"22","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Li C.; Li X.; Wu C.; Zhou H.; Lu S.; Liu X.; Trimetazidine improves hepatic lipogenesis and steatosis in non\u2011alcoholic fatty liver disease via AMPK\u2011ChREBP pathway. Mol Med Rep 2020,22(3),2174-2182","journal-title":"Mol Med Rep"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4103\/0019-5049.115576","volume":"57","author":"Pandey C.K.","year":"2013","unstructured":"Pandey C.K.; Nath S.S.; Pandey V.K.; Karna S.T.; Tandon M.; Perioperative ischaemia-induced liver injury and protection strategies: An expanding horizon for anaesthesiologists. Indian J Anaesth 2013,57(3),223-229","journal-title":"Indian J Anaesth"},{"key":"ref=123","first-page":"569","volume":"56","author":"Settaf A.","year":"2001","unstructured":"Settaf A.; Zaim N.; Bellouch M.; Tillement J.P.; Morin D.; Trimetazidine prevents ischemia-reperfusion injury in hepatic surgery under vascular clamping. Therapie 2001,56(5),569-574","journal-title":"Therapie"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.febslet.2005.01.082","volume":"579","author":"Andela V.B.","year":"2005","unstructured":"Andela V.B.; Altuwaijri S.; Wood J.; Rosier R.N.; Inhibition of &#x3B2;-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. FEBS Lett 2005,579(7),1765-1769","journal-title":"FEBS Lett"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2018.05.017","volume":"430","author":"Halama A.","year":"2018","unstructured":"Halama A.; Kulinski M.; Dib S.S.; Zaghlool S.B.; Siveen K.S.; Iskandarani A.; Zierer J.; Prabhu K.S.; Satheesh N.J.; Bhagwat A.M.; Uddin S.; Kastenm&#xFC;ller G.; Elemento O.; Gross S.S.; Suhre K.; Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. Cancer Lett 2018,430,133-147","journal-title":"Cancer Lett"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e133081","DOI":"10.1172\/JCI133081","volume":"131","author":"Amoedo N.D.","year":"2021","unstructured":"Amoedo N.D.; Sarlak S.; Obre E.; Esteves P.; B&#xE9;gueret H.; Kieffer Y.; Rousseau B.; Dupis A.; Izotte J.; Bellance N.; Dard L.; Redonnet-Vernhet I.; Punzi G.; Rodrigues M.F.; Dumon E.; Mafhouf W.; Guyonnet-Dup&#xE9;rat V.; Gales L.; Palama T.; Bellvert F.; Dugot-Senan N.; Claverol S.; Baste J-M.; Lacombe D.; Rezvani H.R.; Pierri C.L.; Mechta-Grigoriou F.; Thumerel M.; Rossignol R.; Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas. J Clin Invest 2021,131(1),e133081","journal-title":"J Clin Invest"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/106002809102500309","volume":"25","author":"Mauro V.F.","year":"1991","unstructured":"Mauro V.F.; MacDonald J.L.; Simvastatin: A review of its pharmacology and clinical use. DICP 1991,25(3),257-264","journal-title":"DICP"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.thromres.2007.09.017","volume":"122","author":"&#xC5;berg M.","year":"2008","unstructured":"&#xC5;berg M.; Wickstr&#xF6;m M.; Siegbahn A.; Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF\/FVIIa and TF\/FVIIa\/FXa. Thromb Res 2008,122(2),191-202","journal-title":"Thromb Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2006.10.009","volume":"250","author":"Koyuturk M.","year":"2007","unstructured":"Koyuturk M.; Ersoz M.; Altiok N.; Simvastatin induces apoptosis in human breast cancer cells: P53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 2007,250(2),220-228","journal-title":"Cancer Lett"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"44841","DOI":"10.1038\/srep44841","volume":"7","author":"Alizadeh J.","year":"2017","unstructured":"Alizadeh J.; Zeki A.A.; Mirzaei N.; Tewary S.; Rezaei Moghadam A.; Glogowska A.; Nagakannan P.; Eftekharpour E.; Wiechec E.; Gordon J.W.; Xu F.Y.; Field J.T.; Yoneda K.Y.; Kenyon N.J.; Hashemi M.; Hatch G.M.; Hombach-Klonisch S.; Klonisch T.; Ghavami S.; Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci Rep 2017,7(1),44841","journal-title":"Sci Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1158\/0008-5472.CAN-05-4061","volume":"66","author":"Campbell M.J.","year":"2006","unstructured":"Campbell M.J.; Esserman L.J.; Zhou Y.; Shoemaker M.; Lobo M.; Borman E.; Baehner F.; Kumar A.S.; Adduci K.; Marx C.; Petricoin E.F.; Liotta L.A.; Winters M.; Benz S.; Benz C.C.; Breast cancer growth prevention by statins. Cancer Res 2006,66(17),8707-8714","journal-title":"Cancer Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10863-008-9155-9","volume":"40","author":"Oliveira K.A.P.","year":"2008","unstructured":"Oliveira K.A.P.; Zecchin K.G.; Alberici L.C.; Castilho R.F.; Vercesi A.E.; Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction. J Bioenerg Biomembr 2008,40(4),307-314","journal-title":"J Bioenerg Biomembr"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1016\/j.bbagen.2013.04.011","volume":"1830","author":"Chang H.L.","year":"2013","unstructured":"Chang H.L.; Chen C.Y.; Hsu Y.F.; Kuo W.S.; Ou G.; Chiu P.T.; Huang Y.H.; Hsu M.J.; Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. Biochim Biophys Acta 2013,1830(8),4053-4064","journal-title":"Biochim Biophys Acta"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1007\/s13277-015-3134-7","volume":"36","author":"Shang L.","year":"2015","unstructured":"Shang L.; Jia S.S.; Jiang H.M.; Wang H.; Xu W.H.; Lv C.J.; Simvastatin downregulates expression of TGF-&#x3B2;RII and inhibits proliferation of A549 cells via ERK. Tumour Biol 2015,36(6),4819-4824","journal-title":"Tumour Biol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4143\/crt.2013.194","volume":"47","author":"Kim Y.S.","year":"2015","unstructured":"Kim Y.S.; Seol C.H.; Jung J.W.; Oh S.J.; Hwang K.E.; Kim H.J.; Jeong E.T.; Kim H.R.; Synergistic effect of sulindac and simvastatin on apoptosis in lung cancer A549 cells through AKT-dependent downregulation of survivin. Cancer Res Treat 2015,47(1),90-100","journal-title":"Cancer Res Treat"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3727\/096504013X13657689382897","volume":"20","author":"Yu X.","year":"2013","unstructured":"Yu X.; Pan Y.; Ma H.; Li W.; Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. Oncol Res 2013,20(8),351-357","journal-title":"Oncol Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3892\/ijo.2014.2584","volume":"45","author":"Hwang K.E.","year":"2014","unstructured":"Hwang K.E.; Kim Y.S.; Hwang Y.R.; Kwon S.J.; Park D.S.; Cha B.K.; Kim B.R.; Yoon K.H.; Jeong E.T.; Kim H.R.; Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction. Int J Oncol 2014,45(4),1769-1777","journal-title":"Int J Oncol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3892\/ol.2020.12183","volume":"20","author":"Ortiz N.","year":"2020","unstructured":"Ortiz N.; D&#xED;az C.; Mevalonate pathway as a novel target for the treatment of metastatic gastric cancer. Oncol Lett 2020,20(6),320","journal-title":"Oncol Lett"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2147\/OTT.S237693","volume":"13","author":"Liu Q.","year":"2020","unstructured":"Liu Q.; Xia H.; Zhou S.; Tang Q.; Zhou J.; Ren M.; Bi F.; Simvastatin inhibits the malignant behaviors of gastric cancer cells by simultaneously suppressing YAP and &#x3B2;-Catenin Signaling. OncoTargets Ther 2020,13,2057-2066","journal-title":"OncoTargets Ther"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/bjc.2014.54","volume":"110","author":"Beesley A.H.","year":"2014","unstructured":"Beesley A.H.; Stirnweiss A.; Ferrari E.; Endersby R.; Howlett M.; Failes T.W.; Arndt G.M.; Charles A.K.; Cole C.H.; Kees U.R.; Comparative drug screening in NUT midline carcinoma. Br J Cancer 2014,110(5),1189-1198","journal-title":"Br J Cancer"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3892\/ijo.2011.1273","volume":"40","author":"Spampanato C.","year":"2012","unstructured":"Spampanato C.; De Maria S.; Sarnataro M.; Giordano E.; Zanfardino M.; Baiano S.; Carten&#xEC; M.; Morelli F.; Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol 2012,40(4),935-941","journal-title":"Int J Oncol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/febs.15069","volume":"287","author":"Shojaei S.","year":"2020","unstructured":"Shojaei S.; Koleini N.; Samiei E.; Aghaei M.; Cole L.K.; Alizadeh J.; Islam M.I.; Vosoughi A.R.; Albokashy M.; Butterfield Y.; Marzban H.; Xu F.; Thliveris J.; Kardami E.; Hatch G.M.; Eftekharpour E.; Akbari M.; Hombach-Klonisch S.; Klonisch T.; Ghavami S.; Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. FEBS J 2020,287(5),1005-1034","journal-title":"FEBS J"},{"key":"ref=143","first-page":"106","volume":"24","author":"Cheng-Qian Y.","year":"2014","unstructured":"Cheng-Qian Y.; Xin-Jing W.; Xinbing W.; Zhuang-Lei G.; Hong-Peng Z.; Songde X.; Pei-Lin W.; Simvastatin inhibited the growth of gastric cancer cells. UHOD - Uluslararasi Hematol. Derg 2014,24(2),106-111","journal-title":"Derg"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00109-013-1095-0","volume":"92","author":"Manu K.A.","year":"2014","unstructured":"Manu K.A.; Shanmugam M.K.; Li F.; Chen L.; Siveen K.S.; Ahn K.S.; Kumar A.P.; Sethi G.; Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med (Berl) 2014,92(3),267-276","journal-title":"J Mol Med (Berl)"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"152820","DOI":"10.1016\/j.prp.2020.152820","volume":"216","author":"Hong J.Y.","year":"2020","unstructured":"Hong J.Y.; Kim H.J.; Kim K.; Hong J.; Kim J.E.; Byeon S.J.; Lee I.K.; Kim K.M.; Shim M.; Park S.H.; Park J.O.; Park Y.S.; Lim H.Y.; Kim S.T.; Lee J.; Kang W.K.; TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. Pathol Res Pract 2020,216(3),152820","journal-title":"Pathol Res Pract"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41374-019-0193-1","volume":"99","author":"Yun U.J.","year":"2019","unstructured":"Yun U.J.; Lee J.H.; Shim J.; Yoon K.; Goh S.H.; Yi E.H.; Ye S.K.; Lee J.S.; Lee H.; Park J.; Lee I.H.; Kim Y.N.; Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR\/Src pathway. Lab Invest 2019,99(8),1157-1172","journal-title":"Lab Invest"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gene.2016.04.029","volume":"587","author":"Chushi L.","year":"2016","unstructured":"Chushi L.; Wei W.; Kangkang X.; Yongzeng F.; Ning X.; Xiaolei C.; HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene 2016,587(1),42-47","journal-title":"Gene"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/dju405","volume":"107","author":"Baker S.G.","year":"2014","unstructured":"Baker S.G.; A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst 2014,107(2),1-8","journal-title":"J Natl Cancer Inst"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2407-7-151","volume":"7","author":"Baker S.G.","year":"2007","unstructured":"Baker S.G.; Kramer B.S.; Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer 2007,7(1),151","journal-title":"BMC Cancer"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2010.28.5460","volume":"28","author":"Baker S.G.","year":"2010","unstructured":"Baker S.G.; Cappuccio A.; Potter J.D.; Research on early-stage carcinogenesis: Are we approaching paradigm instability? J Clin Oncol 2010,28(20),3215-3218","journal-title":"J Clin Oncol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/bies.20087","volume":"26","author":"Soto A.M.","year":"2004","unstructured":"Soto A.M.; Sonnenschein C.; The somatic mutation theory of cancer: Growing problems with the paradigm? BioEssays 2004,26(10),1097-1107","journal-title":"BioEssays"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4137\/GRSB.S8542","volume":"5","author":"Rosenfeld S.","year":"2011","unstructured":"Rosenfeld S.; Biomolecular self-defense and futility of high-specificity therapeutic targeting. Gene Regul Syst Bio 2011,5(5),89-104","journal-title":"Gene Regul Syst Bio"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1158\/0008-5472.CAN-17-0448","volume":"77","author":"Brock A.","year":"2017","unstructured":"Brock A.; Huang S.; Precision oncology: Between vaguely right and precisely wrong. Cancer Res 2017,77(23),6473-6479","journal-title":"Cancer Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09692290.2019.1659842","volume":"27","author":"Sell S.K.","year":"2020","unstructured":"Sell S.K.; Williams O.D.; Health under Capitalism: A global political economy of structural pathogenesis. Rev Int Polit Econ 2020,27(1),1-25","journal-title":"Rev Int Polit Econ"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12961-018-0365-2","volume":"16","author":"Baru R.V.","year":"2018","unstructured":"Baru R.V.; Mohan M.; Globalisation and neoliberalism as structural drivers of health inequities. Health Res Policy Syst 2018,16(Suppl. 1),91","journal-title":"Health Res Policy Syst"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.5779\/hypothesis.v12i1.229","volume":"12","author":"Birn A.E.","year":"2014","unstructured":"Birn A.E.; Philanthrocapitalism, Past and present: The rockefeller foundation, the gates foundation, and the setting(s) of the international\/global health agenda. Hypothesis 2014,12(1),e8","journal-title":"Hypothesis"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrg3934","volume":"16","author":"Parikshak N.N.","year":"2015","unstructured":"Parikshak N.N.; Gandal M.J.; Geschwind D.H.; Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet 2015,16(8),441-458","journal-title":"Nat Rev Genet"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cels.2017.01.005","volume":"4","author":"Baliga N.S.","year":"2017","unstructured":"Baliga N.S.; Bj&#xF6;rkegren J.L.M.; Boeke J.D.; Boutros M.; Crawford N.P.S.; Dudley A.M.; Farber C.R.; Jones A.; Levey A.I.; Lusis A.J.; Mak H.C.; Nadeau J.H.; Noyes M.B.; Petretto E.; Seyfried N.T.; Steinmetz L.M.; Vonesch S.C.; The state of systems genetics in 2017. Cell Syst 2017,4(1),7-15","journal-title":"Cell Syst"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc1300","volume":"4","author":"Kitano H.","year":"2004","unstructured":"Kitano H.; Cancer as a robust system: Implications for anticancer therapy. Nat Rev Cancer 2004,4(3),227-235","journal-title":"Nat Rev Cancer"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cell.2004.09.008","volume":"118","author":"Stelling J.","year":"2004","unstructured":"Stelling J.; Sauer U.; Szallasi Z.; Doyle F.J.; Doyle J.; Robustness of cellular functions. Cell 2004,118(6),675-685","journal-title":"Cell"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40487-017-0047-1","volume":"5","author":"Adjiri A.","year":"2017","unstructured":"Adjiri A.; DNA mutations may not be the cause of cancer. Oncol Ther 2017,5(1),85-101","journal-title":"Oncol Ther"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"051909","DOI":"10.1103\/PhysRevE.71.051909","volume":"71","author":"Agoston V.","year":"2005","unstructured":"Agoston V.; Csermely P.; Pongor S.; Multiple weak hits confuse complex systems: A transcriptional regulatory network as an example. Phys Rev E Stat Nonlin Soft Matter Phys 2005,71(5 Pt 1),051909","journal-title":"Phys Rev E Stat Nonlin Soft Matter Phys"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3332\/ecancer.2018.886","volume":"12","author":"Pantziarka P.","year":"2018","unstructured":"Pantziarka P.; Verbaanderd C.; Sukhatme V.; Rica Capistrano I.; Crispino S.; Gyawali B.; Rooman I.; Van Nuffel A.M.T.; Meheus L.; Sukhatme V.P.; Bouche G.; ReDO_DB: The repurposing drugs in oncology database. Ecancermedicalscience 2018,12,886","journal-title":"Ecancermedicalscience"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000336483","volume":"82","author":"Zapletalova D.","year":"2012","unstructured":"Zapletalova D.; Andr&#xE9; N.; Deak L.; Kyr M.; Bajciova V.; Mudry P.; Dubska L.; Demlova R.; Pavelka Z.; Zitterbart K.; Skotakova J.; Husek K.; Martincekova A.; Mazanek P.; Kepak T.; Doubek M.; Kutnikova L.; Valik D.; Sterba J.; Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: A multicenter experience. Oncology 2012,82(5),249-260","journal-title":"Oncology"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/BCTT.S139963","volume":"9","author":"Kast R.E.","year":"2017","unstructured":"Kast R.E.; Skuli N.; Cos S.; Karpel-Massler G.; Shiozawa Y.; Goshen R.; Halatsch M.E.; The ABC7 regimen: A new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer (Dove Med Press) 2017,9,495-514","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.18632\/oncotarget.2408","volume":"5","author":"Kast R.E.","year":"2014","unstructured":"Kast R.E.; Karpel-Massler G.; Halatsch M-E.; CUSP9* treatment protocol for recurrent glioblastoma: Aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 2014,5(18),8052-8082","journal-title":"Oncotarget"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00002826-199304000-00008","volume":"16","author":"Durif F.","year":"1993","unstructured":"Durif F.; Paire M.; Deffond D.; Eschalier A.; Dordain G.; Tournilhac M.; Lavarenne J.; Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson\u2019s disease. Clin Neuropharmacol 1993,16(2),157-166","journal-title":"Clin Neuropharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s10637-014-0159-5","volume":"32","author":"Brana I.","year":"2014","unstructured":"Brana I.; Ocana A.; Chen E.X.; Razak A.R.A.; Haines C.; Lee C.; Douglas S.; Wang L.; Siu L.L.; Tannock I.F.; Bedard P.L.; A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs 2014,32(6),1269-1277","journal-title":"Invest New Drugs"},{"key":"ref=169","first-page":"CD003614","volume":"3","author":"Ciapponi A.","year":"2017","unstructured":"Ciapponi A.; Pizarro R.; Harrison J.; WITHDRAWN: Trimetazidine for stable angina. Cochrane Database Syst Rev 2017,3(3),CD003614","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12793\/tcp.2017.25.1.10","volume":"25","author":"Moon S.J.","year":"2017","unstructured":"Moon S.J.; Lee S.; Jang K.; Yu K.S.; Yim S.V.; Kim B.H.; Comparative pharmacokinetic and tolerability evaluation of two simvastatin 20 mg formulations in healthy Korean male volunteers. Transl Clin Pharmacol 2017,25(1),10-14","journal-title":"Transl Clin Pharmacol"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467214666211006123728","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197040\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467214666211006123728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:57:49Z","timestamp":1746572269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197040\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":170,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467214666211006123728","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}